SIS-E 2019 are delighted to have the following partners confirmed
KCI, an Acelity Company, is a global advanced wound care company committed to developing innovative healing solutions for customers and patients across the wound care continuum. We deliver value through solutions that aim to speed healing and lead the industry in quality, safety and customer experience, offering unparalleled service to support clinicians in the management of patients and therapies.
Available in 90 countries, KCI products offer wound healing solutions to manage all types of wounds including complex acute and chronic wounds, open abdomen and closed surgical incisions. Headquartered in San Antonio, Texas, Acelity employs nearly 5,000 people around the world.
We have a global commitment to advancing the science of healing. Our portfolio includes negative pressure wound therapy, advanced wound dressings, negative pressure surgical incision management and epidermal harvesting.
About Johnson & Johnson Medical Devices Companies
As the world’s most comprehensive medical devices business, we are building on a century of experience, merging science and technology, to shape the future of health and benefit even more people around the world. With our unparalleled breadth, depth and reach across surgery, orthopaedics, vision and interventional solutions, we’re working to profoundly change the way care is delivered. We are in this for life.
Ethicon, part of Johnson & Johnson Medical Devices Companies, has made significant contributions to surgery for more than 100 years from creating the first sutures, to revolutionizing surgery with minimally invasive procedures. Our continuing dedication to Shape the Future of Surgery is built on our commitment to help address the world’s most pressing health care issues and improve and save more lives. Through Ethicon’s surgical technologies and solutions including sutures, staplers, energy devices, trocars and adjunctive hemostats and our commitment to treat serious medical conditions like obesity and cancer worldwide, we deliver innovation to make a life-changing impact. For more information, visit www.ethicon.com.
Intra-operative SSI prevention measures and outcome assessments
Thursday June 27th 14:00-15:00
BD is one of the largest global medical technology companies and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. In 2017, BD welcomed C.R. Bard into the BD family and through this collaboration is accelerating the delivery of innovative technologies, world-class clinical education, and disease awareness programs that are helping to transform the standard of patient care. BD.com
TELA Bio is a surgical reconstruction company and is taking a fresh look at soft tissue reinforcement to reduce the inherent trade-offs between synthetic and biologic materials.
OviTex® Reinforced Biologics are a new class of implants designed for use in hernia repair and abdominal wall reconstruction which combine biologic and synthetic materials in a unique embroidered construction designed to surpass the performance of existing products. The biologic material serves as a scaffold for cellular repopulation, revascularization and tissue remodelling, while the polymer provides additional strength.
NewCompliance develops the OR Cockpit; a revolutionary interoperability solution for the surgery department. It optimizes OR productivity, minimizes surgical site infections (SSI’s), reduces material costs and provides unprecedented clinical performance analytics & reporting by integrating data from the EMR, BMS & other OR equipment. The system allows surgical teams to benefit from smart and real-time visual decision support, perfect workflow control and swifter safety protocols, all through one central system which is easily operated through large wall-mounted touchscreen displays. NewCompliance is a market leader for Safe Surgery dashboarding, running live in over 35 health systems around the world.
The Adtec SteriPlas is a topical antimicrobial medical device that can be used to successfully manage infection in chronic wounds, surgical site infections and dermatological conditions. This includes problematic conditions such as diabetic foot ulcers where conventional treatment methods may find difficulty to treat if biofilm is present. A 2 minute treatment covering a 12cm2 area with proven RCT evidence of microbial load reduction including multi-resistant bacteria.
Smith & Nephew
Smith & Nephew Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, to help healthcare professionals get CLOSER TO ZERO human and economic consequences of wounds.
26 - 28 June 2019
End of Early Bird Registration
10 April 2019
Accepted authors to confirm
30 April 2019